SCIPain after spinal cord injury is one of the most undertreated, misunderstood, and debilitating aspects of life with SCI. Up to 80% of people with SCI experience chronic pain — and of those, roughly one-third describe it as severe. Yet the standard of care remains inadequate, trial-and-error-heavy, and often managed by clinicians who don't specialize in SCI-specific pain.
This article covers every treatment worth knowing about, what the evidence actually says, and the hard-won knowledge from the SCI community about what actually moves the needle.
This is plain-language patient education to help you have a better-informed conversation with your care team — it is not medical advice and not a treatment plan. Every medication here is prescription (or otherwise needs professional guidance), dosing must be individualized, and several combinations carry real risks. Names, doses, and approvals differ by country and change over time.
Use it to learn the landscape and to build your questions. Your doctor and pharmacist know your full situation; this page does not.
The Different Types of Pain After SCI
Not all pain after SCI is the same. Getting the diagnosis right determines whether the treatment you try has any chance of working.
Neuropathic pain — Pain caused by damage to the nervous system itself, not by tissue injury. Feels like burning, electric shocks, stabbing, or deep aching. Located at or below the level of injury. This is the most common and hardest-to-treat type.
Musculoskeletal pain — Pain from overuse, poor posture, or strain — especially in the shoulders, neck, and wrists from wheelchair pushing and transfers. This responds to conventional pain management better than neuropathic pain.
Visceral pain — Pain from internal organs, often vague and crampy. Can be related to bowel, bladder, or other organ issues. Frequently mistaken for neuropathic pain.
Spasm-related pain — Pain caused directly by spasms or spasticity. See the Spasticity & Spasms article.
Neuropathic Pain: What's Actually Happening
When the spinal cord is injured, the nervous system above and below the injury doesn't simply go quiet. It reorganizes — and often that reorganization goes wrong. Neurons that no longer receive normal input become hyperexcitable. They fire spontaneously. They amplify signals that shouldn't be painful. They create pain that has no protective purpose and no peripheral cause.
This is why neuropathic pain is so treatment-resistant: you can't fix it by treating the injury site. You have to change how the nervous system itself processes signals — which is why the drugs that work are primarily neurologically active, not traditional painkillers.
Allodynia: When Normal Touch Causes Pain
Allodynia is one of the cruelest manifestations of SCI neuropathic pain. It's the experience of normal, non-painful stimuli — a light touch, bedsheets on your skin, a breeze, temperature change — causing genuine pain.
For many people with SCI, particularly those with central cord syndrome or incomplete injuries where some sensation is preserved, allodynia is constant and disabling. A shirt sleeve. A handshake. The seat pressing against preserved skin. All of it painful.
Allodynia is a sign of central sensitization — the nervous system has been wound up to a state where its threshold for perceiving pain has been dramatically lowered.
Central Sensitization: The Underlying Mechanism
Central sensitization is the process by which the central nervous system becomes amplified — more sensitive, more reactive, generating more pain from less stimulus. After SCI, the damaged cord disrupts normal inhibitory signals that would keep sensory neurons in check. Without that inhibition, neurons in the pain pathway become chronically activated.
NMDA receptors play a central role in this process. When these receptors are activated by glutamate — released by firing pain neurons — they become more excitable. This is "wind-up": the more the system fires, the easier it fires. This is why NMDA receptor antagonists (ketamine, methadone, memantine) are specifically interesting for SCI pain — they address the underlying mechanism rather than just masking the output.
For neuropathic pain, a treatment that reduces pain by 30–50% is considered a meaningful success in the research. Few medications eliminate this pain entirely. Layering modest gains — a medication, a topical, a non-drug therapy, better sleep — often does more than chasing a single “cure.” If pain suddenly worsens or changes character years after injury, tell your doctor: it can signal a new problem such as a syrinx (a fluid-filled cavity in the cord) that needs its own work-up.
How doctors approach treatment
International guidelines broadly agree on an order of preference, based on evidence strength and risk balance. The lines below are a map, not a rulebook — your clinician will tailor the route to your body, other conditions, and what has or hasn't worked.
| Tier | Typical options | Idea |
|---|---|---|
| First-line | Gabapentinoids (gabapentin, pregabalin); SNRIs (duloxetine, venlafaxine); tricyclics (amitriptyline, nortriptyline) | Best evidence and risk balance; the usual starting points for SCI nerve pain. |
| Second-line | Combining two first-line drugs; tramadol or tapentadol; high-concentration capsaicin or lidocaine patches for focal pain; botulinum toxin | Added when single agents fall short, or for localized pain. |
| Later-line | Cannabinoids; certain other anticonvulsants; NMDA agents (ketamine); strong opioids (last resort); interventional and intrathecal therapies; neurostimulation | For pain that resists the above, usually via a pain specialist. |
A 2024 multicenter survey of people with SCI found something worth knowing: respondents often rated opioids, cannabinoids, and massage as more helpful than the antiseizure and antidepressant drugs that guidelines put first. The guideline ordering reflects safety and the strength of formal trials — but your lived experience is real data too, and it's a fair thing to raise with your doctor when weighing options.
Before the drug list — two safety essentials
Serotonin syndrome: several of these drugs raise serotonin — tramadol, duloxetine, venlafaxine, tricyclics, SSRIs, and others. Stacking them can, rarely, cause a serious reaction (agitation, fever, racing heart, shivering, confusion). Your prescriber and pharmacist need to see your full list, including over-the-counter items and supplements.
Over-sedation and slowed breathing: opioids, gabapentin/pregabalin, benzodiazepines (e.g., diazepam, baclofen at high dose), and alcohol all depress the nervous system. Combined, the risk of dangerous sedation and respiratory depression rises sharply. Combinations like this should only happen under medical guidance.
Many of these medications must be started low and increased slowly, and several must be tapered rather than stopped abruptly (stopping gabapentinoids, antidepressants, or opioids suddenly can cause withdrawal or rebound symptoms). The doses below are typical ranges from the literature for discussion — your actual dose depends on your kidney and liver function, age, other medicines, and response.
First-line oral medications
These are the usual starting points: the gabapentinoids and two families of antidepressants used at pain (not always full antidepressant) doses. Many people eventually combine one gabapentinoid with one antidepressant.
Gabapentin
How it helps. A first-choice option for SCI nerve pain. It calms over-excitable nerves by binding the α2δ subunit of calcium channels, dialing down the abnormal signaling that drives burning and shooting pain.
Common side effects. Drowsiness, dizziness, unsteadiness, ankle swelling, weight gain, and sometimes brain fog. These often ease over the first couple of weeks.
Key cautions. Taper rather than stop abruptly. Combined with opioids it adds sedation/breathing risk. Misuse is uncommon but recognized, especially alongside opioids or alcohol.
SCI & evidence note. Has direct randomized evidence in SCI nerve pain and is widely considered a first-line agent for it. Three-times-daily dosing matters — under-titrated once-daily use is a common reason it 'doesn't work.'
→ SCI guideline summary (Bryce 2024)
Pregabalin
How it helps. Same mechanism as gabapentin (α2δ calcium-channel binding) but absorbed more predictably, so dosing is simpler and the response can come a little faster. One of the best-studied drugs for SCI nerve pain specifically.
Common side effects. Dizziness, sleepiness, swelling, weight gain, and occasionally blurred vision or mood change.
Key cautions. Taper to stop. Same additive-sedation caution with opioids/alcohol. A controlled substance in some regions due to misuse potential.
SCI & evidence note. Carries some of the strongest SCI-specific trial support of any oral drug, which is why many specialists reach for it early.
→ Neuropathic pain dosing summary
Mirogabalin
How it helps. A newer gabapentinoid (α2δ ligand) developed in Asia, notable because it was tested in a large Phase 3 trial specifically for central neuropathic pain after spinal cord injury.
Common side effects. Similar to other gabapentinoids — dizziness, sleepiness, swelling.
Key cautions. Same gabapentinoid cautions apply.
SCI & evidence note. Approved in Japan, Korea, and Taiwan; not FDA-approved in the US or available in many countries. Included here because the SCI-specific evidence is relevant and you may encounter it in research.
→ Mirogabalin SCI trial (Neurology)
Duloxetine
How it helps. An SNRI antidepressant that relieves nerve pain by boosting the body's own descending pain-dampening pathways (serotonin and norepinephrine). Helpful when low mood or poor sleep travel alongside the pain.
Common side effects. Nausea (often early and temporary), dry mouth, sleepiness or insomnia, sweating, constipation.
Key cautions. Avoid in significant liver disease; can raise blood pressure; taper to stop. Counts toward serotonin load — flag all serotonergic drugs.
SCI & evidence note. A standard first-line choice across guidelines for nerve pain, including in SCI.
Venlafaxine
How it helps. An SNRI in the same family as duloxetine; its norepinephrine effect (which helps nerve pain most) is strongest at higher doses.
Common side effects. Nausea, sweating, sleep changes, and blood-pressure elevation at higher doses.
Key cautions. Monitor blood pressure; taper carefully (abrupt stop causes pronounced discontinuation symptoms). Serotonergic.
SCI & evidence note. A reasonable first-line antidepressant option when duloxetine isn't suitable. Milnacipran is a related SNRI used more for fibromyalgia.
Amitriptyline
How it helps. A tricyclic antidepressant — one of the oldest and best-studied nerve-pain drugs, and among the most-studied in SCI. Works on multiple pain pathways and often improves sleep at low doses.
Common side effects. Dry mouth, constipation, drowsiness, blurred vision, urinary hesitancy, weight gain.
Key cautions. Anticholinergic effects make it a poor fit for older adults, glaucoma, urinary retention, or heart-rhythm problems; doses above ~100 mg/day raise cardiac risk. Taper to stop.
SCI & evidence note. Strong, long-standing evidence in SCI nerve pain — but the side-effect profile means many clinicians now favor nortriptyline for better tolerability.
Nortriptyline
How it helps. A tricyclic closely related to amitriptyline but usually better tolerated (less sedation and fewer anticholinergic effects), making it a common first-tricyclic choice. Desipramine and imipramine are alternatives.
Common side effects. Similar to amitriptyline but generally milder; dry mouth, constipation, drowsiness.
Key cautions. Same cardiac/anticholinergic cautions as the class, to a lesser degree. Taper to stop.
SCI & evidence note. Reasonable first-line tricyclic, particularly when amitriptyline's side effects are limiting.
Topical treatments
For pain concentrated in a specific area, treatments you put on the skin can help with little or no whole-body burden — useful on their own or layered onto oral drugs.
Lidocaine 5% patch
How it helps. A numbing patch applied over a painful, well-localized area. It quiets overactive surface nerves with almost no drug reaching the bloodstream — so it's one of the safest options and pairs well with pills.
Common side effects. Mild skin redness or irritation where applied.
Key cautions. Excellent safety profile; main limitation is that it only helps where you can place it, so it suits focal pain better than widespread pain.
SCI & evidence note. FDA-approved for post-shingles nerve pain; used off-label for focal SCI/peripheral pain. A sensible early add-on because the risk is so low.
→ Topical analgesics clinical guide
Capsaicin 8% patch
How it helps. A high-concentration chili-pepper patch applied in the clinic. It temporarily 'defunctionalizes' the tiny pain fibers in the skin; relief can build over days and last around 3 months, after which it can be repeated.
Common side effects. Burning, stinging, and redness during/after application; a transient blood-pressure rise can occur during treatment.
Key cautions. Must be applied under supervision. Long-term repeated use and effects on already-damaged nerve fibers aren't fully characterized.
SCI & evidence note. FDA-approved for post-shingles pain and diabetic foot neuropathy; studied directly in SCI nerve pain (e.g., a UT San Antonio crossover trial). A genuine option for focal below-level pain.
Compounded topical creams
How it helps. Pharmacy-mixed creams combining nerve-pain ingredients for direct skin application. Appealing because they avoid whole-body side effects, but the evidence is mixed and quality varies by pharmacy.
Common side effects. Usually minor skin irritation; systemic side effects are uncommon at typical strengths.
Key cautions. Not standardized or generally FDA-approved as compounds; insurance coverage is inconsistent. Best guided by a pain specialist.
SCI & evidence note. Amitriptyline and gabapentin compounds have the more supportive data among topicals; topical ketamine results are weak.
Other anticonvulsants & sodium-channel drugs
Beyond the gabapentinoids, several antiseizure medicines are sometimes used — most often for sharp, electric, shooting pain, and usually after first-line options. Evidence here is weaker, so these tend to be specialist choices.
Oxcarbazepine & carbamazepine
How it helps. Sodium-channel–blocking antiseizure drugs. They are the go-to for trigeminal neuralgia, and are sometimes tried for SCI pain with a strong electric, shooting, paroxysmal quality.
Common side effects. Dizziness, drowsiness, double vision, low sodium (especially oxcarbazepine); carbamazepine can affect blood counts and the liver.
Key cautions. Many drug interactions; requires lab monitoring; serious skin reactions are rare but possible (genetic testing is advised in some populations before carbamazepine).
SCI & evidence note. Limited evidence for general/SCI nerve pain and frequent side effects mean these are case-by-case rather than routine.
→ German Society of Neurology guideline
Lamotrigine, lacosamide, topiramate, valproate
How it helps. Other antiseizure medicines occasionally used when first-line drugs fail. Lacosamide and lamotrigine act on sodium channels; topiramate and valproate work more broadly. Evidence in nerve pain is modest and inconsistent.
Common side effects. Vary by drug: lamotrigine — rash (rarely serious); topiramate — tingling, word-finding trouble, weight loss, kidney stones; valproate — weight gain, tremor, liver/blood effects (and major pregnancy risks).
Key cautions. Valproate must be avoided in pregnancy/those who may become pregnant. Each carries its own monitoring needs.
SCI & evidence note. Reserved for refractory cases; not first or second choices for SCI nerve pain.
Mexiletine
How it helps. An oral cousin of lidocaine (a systemic sodium-channel blocker), occasionally tried for severe, refractory nerve pain.
Common side effects. Nausea, tremor, dizziness; can affect heart rhythm.
Key cautions. Requires cardiac caution and monitoring; interactions matter.
SCI & evidence note. A niche option for treatment-resistant pain in experienced hands.
SSRIs — a clear-eyed note
SSRIs come up often in these conversations, so here is the honest picture for nerve pain specifically.
SSRIs
How it helps. Selective serotonin reuptake inhibitors raise serotonin only — and for nerve pain that appears to matter less than the dual serotonin-plus-norepinephrine action of SNRIs and tricyclics.
Common side effects. Nausea, sleep and sexual side effects, headache.
Key cautions. Generally taper to stop; serotonergic (interaction caution, e.g., with tramadol).
SCI & evidence note. For neuropathic pain itself, SSRIs are usually less effective than SNRIs or tricyclics. Their main role is treating co-existing depression or anxiety, which can in turn make pain easier to cope with — a real, if indirect, benefit.
Opioids — honest placement
Opioids are widely used and, surveys show, many people with SCI find them helpful. But for nerve pain specifically the formal evidence is mixed and the long-term risks are real, so guidelines place them later — gentler agents (tramadol, tapentadol) before stronger ones, and strong opioids as a last resort. The goal of this section is informed, careful conversation, not encouragement.
Tramadol
How it helps. A weaker opioid that also mildly inhibits serotonin and norepinephrine reuptake (like an antidepressant), which is why it has some specific nerve-pain benefit. Sits at the gentler end of the opioid options.
Common side effects. Nausea, dizziness, constipation, sleepiness; lowers the seizure threshold.
Key cautions. Notable serotonin-syndrome risk when combined with SNRIs, SSRIs, or tricyclics — a common and important interaction. Still carries dependence and withdrawal potential.
SCI & evidence note. A recognized second-line option with a number-needed-to-treat around 4 in nerve pain. Often tried before stronger opioids.
→ Opioids for neuropathic pain
Tapentadol
How it helps. Combines mu-opioid action with norepinephrine reuptake inhibition in one molecule — the second mechanism gives it particular nerve-pain activity. It is the only opioid FDA-approved for a neuropathic indication (diabetic peripheral neuropathy).
Common side effects. Nausea and constipation, but generally better gastrointestinal tolerance than older opioids; dizziness, sleepiness.
Key cautions. Lower reported misuse potential than traditional opioids, but it remains a controlled opioid with dependence risk; serotonergic caution.
SCI & evidence note. A reasonable second-line opioid when one is warranted, given its dual mechanism and tolerability.
Stronger opioids
How it helps. Conventional strong opioids. They can blunt many kinds of pain but show inconsistent results for central nerve pain and carry the most serious long-term risks. Methadone and levorphanol additionally block NMDA receptors, and buprenorphine has a unique receptor profile — properties some specialists consider theoretically favorable for nerve pain.
Common side effects. Constipation, sedation, nausea, itching; with time, tolerance, physical dependence, hormonal effects, and — critically — risk of overdose.
Key cautions. Highest-risk category here. Slowed breathing and overdose risk climb when combined with gabapentinoids, benzodiazepines, or alcohol. Dependence and withdrawal are expected with ongoing use; never adjust abruptly.
SCI & evidence note. Guidelines place strong opioids as a late-line / last-resort option for SCI nerve pain because evidence is weak and harms are high. This is the area where 'ask your doctor' matters most — including asking about an exit plan from the start.
Cannabinoids — THC, CBD & prescription forms
This is one of the most-asked-about areas, so it gets full treatment. The honest summary: formal evidence is modest and variable, but many people with SCI report meaningful help — making it a reasonable later-line conversation where it is legal and appropriate.
Medical cannabis (THC : CBD)
How it helps. Cannabis acts on the body's endocannabinoid system. THC is the main pain-active, psychoactive component; CBD is non-intoxicating and may temper THC's side effects. SCI/central-pain studies (including vaporized cannabis) have shown real but modest pain reductions.
Common side effects. Dizziness, dry mouth, altered thinking/memory, fatigue, and — with higher THC — anxiety or euphoria.
Key cautions. Legality, product quality, and consistency vary enormously by location; impairment affects driving; interactions and dependence are possible. Discuss honestly with your clinician, including with other sedating drugs.
SCI & evidence note. Cochrane and other reviews rate the overall evidence low-to-moderate — helpful for some, modest on average — yet patients with SCI frequently rate it among the more helpful options. A legitimate later-line discussion.
→ Cochrane review: cannabis for neuropathic pain
Nabiximols
How it helps. A pharmaceutical oromucosal spray with a fixed ~1:1 THC:CBD ratio (2.7 mg THC + 2.5 mg CBD per spray) — standardized dosing rather than variable plant material. Approved in Canada and parts of Europe for MS-related central nerve pain and spasticity.
Common side effects. Mouth/throat irritation, dizziness, fatigue, altered thinking.
Key cautions. Not FDA-approved in the US. Same impairment and interaction cautions as other cannabinoids.
SCI & evidence note. Among the better-studied cannabinoids for central nerve pain (largely in MS, which overlaps mechanistically with SCI).
→ Cannabis-based medicines review
Dronabinol & nabilone
How it helps. Prescription synthetic-THC capsules (dronabinol) and a THC analogue (nabilone), FDA-approved for chemo nausea and appetite — sometimes used off-label for nerve pain and spasticity.
Common side effects. Sedation, dizziness, dysphoria; oral THC's effects can be unpredictable in timing and intensity.
Key cautions. Controlled substances; oral-only THC tends to cause more sedation/dropouts than balanced THC:CBD in trials. In one SCI study some people improved while others' pain worsened.
SCI & evidence note. Evidence is limited and mixed; balanced THC:CBD products generally outperform THC-only forms.
CBD alone
How it helps. Non-intoxicating cannabidiol, popular over-the-counter. For pain specifically, evidence that CBD on its own helps is weak; its clearest medical use is certain epilepsies (prescription Epidiolex).
Common side effects. Generally well tolerated; can interact with other medications via the liver.
Key cautions. Quality/labeling are inconsistent in OTC products; tell your clinician about interactions.
SCI & evidence note. Reasonable to discuss, but temper expectations for pain relief from CBD by itself.
NMDA-receptor agents
These target the receptor most tied to "central sensitization," where the nervous system becomes locked into amplifying pain — relevant to SCI. Mostly reserved for refractory cases.
Ketamine (infusions)
How it helps. An NMDA-receptor blocker that can interrupt the 'wind-up' and central sensitization underlying stubborn nerve pain. Given as supervised IV infusions for severe, refractory pain, sometimes over several days.
Common side effects. Dissociation, vivid dreams or hallucinations, raised blood pressure/heart rate, nausea (often managed with adjunct medicines and monitoring).
Key cautions. Hospital/clinic setting with monitoring; repeated or recreational use carries bladder and cognitive risks.
SCI & evidence note. Evidence is limited and protocols aren't standardized, but it's a recognized option for intractable nerve pain at specialized centers.
→ IV ketamine for neuropathic pain
Dextromethorphan & memantine
How it helps. Oral NMDA-blocking drugs explored as gentler alternatives to ketamine. Evidence for nerve pain is limited and they are not standard therapy.
Common side effects. Dizziness, sedation; dextromethorphan has interaction and misuse considerations.
Key cautions. Modest, inconsistent data.
SCI & evidence note. Occasionally considered; not a mainstay.
Antispasticity medicines (the pain overlap)
These aren't nerve-pain drugs per se, but after SCI, spasticity and pain are deeply linked — and treating tight, spasming muscles frequently turns down the pain too. Worth knowing about as part of the whole picture. See the Spasticity & Spasms article for full coverage.
Baclofen
How it helps. A muscle relaxant that calms spasticity. Because tight, spastic muscles and spasms generate their own pain, easing spasticity often reduces pain too — and the relationship between spasticity and neuropathic pain in SCI is intertwined.
Common side effects. Drowsiness, weakness, dizziness; pump therapy has device-related considerations.
Key cautions. Never stop abruptly — sudden withdrawal (especially from a pump) can be dangerous. Adds to sedation with other CNS depressants.
SCI & evidence note. Mainly an antispasticity drug, but genuinely relevant to SCI pain through that route.
Tizanidine & clonidine
How it helps. Alpha-2 agonists that reduce spasticity (tizanidine) and can modulate pain signaling (clonidine, sometimes used in nerve blocks or intrathecally). Tizanidine is a common antispasticity choice; clonidine also lowers blood pressure.
Common side effects. Drowsiness, dry mouth, low blood pressure; tizanidine needs occasional liver checks.
Key cautions. Avoid abrupt clonidine withdrawal (rebound hypertension). Additive sedation/hypotension with other drugs.
SCI & evidence note. Adjuncts where spasticity and pain coexist, which is common after SCI.
Injectable, intrathecal & stimulation options
When swallowed pills aren't enough, medicine can be delivered where it's needed — injected into tissue or pumped into the spinal fluid. These are specialist procedures, generally for focal or refractory pain. Implanted neurostimulators are covered at the end of this section.
Botulinum toxin A
How it helps. Injected locally, botulinum toxin is best known for muscles, but it also appears to dampen pain-signaling chemicals released by sensory nerves. Emerging evidence supports it for several focal nerve-pain conditions, including some reports in SCI and post-stroke pain.
Common side effects. Injection-site soreness; unwanted local weakness if it spreads.
Key cautions. Specialized procedure; benefit is most consistent for focal/localized pain.
SCI & evidence note. Considered when first-line drugs fail for focal pain; trial designs are still maturing.
→ Botulinum toxin for neuropathic pain
Intrathecal ziconotide
How it helps. A non-opioid N-type calcium-channel blocker delivered straight into the spinal fluid by an implanted pump. Powerful for severe refractory pain, and — unlike opioids — it doesn't cause tolerance or dependence. It has been studied in refractory SCI pain.
Common side effects. Dizziness, nausea, confusion, mood or memory changes; it has a narrow therapeutic window, so careful titration is essential.
Key cautions. Implant procedure and ongoing pump management; close monitoring for neuropsychiatric effects.
SCI & evidence note. An option for severe, treatment-resistant pain when systemic drugs fail. Pumps can also deliver intrathecal opioids or baclofen.
→ Intrathecal ziconotide in SCI (trial)
Spinal cord stimulation (SCS)
Implanted electrodes deliver mild electrical current to the dorsal columns of the spinal cord, modulating pain signals. Standard SCS — distinct from epidural stimulation for motor recovery — has evidence for some types of SCI pain, particularly at-level neuropathic pain. It is not universally effective and requires surgical implantation and ongoing programming. See the Spinal Cord Stimulators & Neurostimulation article for the full picture.
Brain stimulation: rTMS & tDCS
Repetitive transcranial magnetic stimulation (rTMS) of the motor cortex is non-invasive, with some evidence for SCI neuropathic pain; it is available at some academic centers and not always insured. Transcranial direct current stimulation (tDCS) applies low-level current to the scalp — research support exists but it is not yet widely available clinically.
TENS
Transcutaneous electrical nerve stimulation applied above the injury level is low-risk and gives temporary relief for some people — worth trying given how benign it is.
On the horizon
The pain field is finally producing new mechanisms. The headline arrival is a non-opioid pill with a brand-new target — promising, with an honest asterisk for central SCI pain.
Suzetrigine
How it helps. The first genuinely new kind of pain medicine approved in decades: an oral blocker of the Nav1.8 sodium channel that works on peripheral pain-sensing nerves without entering the brain — so it relieves pain without opioid-style sedation, dependence, or breathing risk. FDA-approved in January 2025 for moderate-to-severe acute pain.
Common side effects. Generally mild in trials — itching, muscle spasms, rash reported; long-term profile still being characterized.
Key cautions. Approved for acute pain; chronic and neuropathic uses are still under study.
SCI & evidence note. Important caveat for SCI: because it acts on peripheral nerves and SCI pain is largely central, its usefulness for SCI burning pain is unproven. Vertex is studying it in diabetic neuropathy and back/leg nerve pain. Included as a development genuinely worth watching.
Supplements & nutraceuticals
Common, low-risk, and frequently asked about — with realistic expectations attached.
Supplements & nutraceuticals
How it helps. Several non-prescription compounds are popular for nerve pain. The most-studied — alpha-lipoic acid and acetyl-L-carnitine — come mostly from diabetic neuropathy research, with mixed and generally modest results; recent reviews have been lukewarm. Vitamin B12 helps most when there's a true deficiency (worth checking). PEA (palmitoylethanolamide) is an anti-inflammatory compound with early, limited supportive data.
Common side effects. Usually well tolerated; specific cautions exist (e.g., very high alpha-lipoic acid has rare serious reports).
Key cautions. "Natural" doesn't mean risk-free — supplements can interact with prescriptions and aren't tightly regulated. Tell your clinician and pharmacist what you take.
SCI & evidence note. Reasonable to discuss as low-risk add-ons, especially correcting a B12 deficiency — but not substitutes for proven therapies.
Beyond medication: non-drug approaches that help
Drugs are only part of the toolkit, and the best results usually combine approaches. Several non-drug strategies have evidence or strong patient support for SCI pain:
- Exercise & activity-based therapy — Movement and conditioning, including activity-based training below the level of injury, can reduce neuropathic pain for some people and supports overall function.
- Psychological therapies — CBT for chronic pain, acceptance and commitment therapy (ACT), and mindfulness don’t mean the pain is “in your head”; they measurably change how the nervous system processes pain and how livable it feels. Pain catastrophizing makes SCI pain worse, and these approaches target it directly.
- Sleep — Poor sleep dramatically worsens neuropathic pain. Treating sleep problems — with positioning, behavior change, or medication — is a legitimate pain strategy.
- Heat & cold — Many people find heat (a pad above the level of injury) eases central pain. Cold is trickier: temperature regulation is impaired after SCI, and cold below the injury can trigger spasms or autonomic dysreflexia.
- Acupuncture & massage — Among the non-drug options people with SCI most often rate as helpful.
Chronic pain wears on mood, sleep, and hope, and the two-way street between pain and low mood is well documented. That’s not weakness — it’s physiology. If pain is dragging your mental health down, that’s worth treating directly and openly with your care team. Reaching out is a strength.
Combination Strategies: What Most People End Up On
Most people with significant SCI neuropathic pain end up on a combination approach. A typical multi-modal regimen might look like:
- Pregabalin (Lyrica) at night for baseline neuropathic pain
- Duloxetine during the day for additional pain modulation and mood support
- Baclofen for spasticity/spasm pain
- Cannabis in the evening for pain, spasticity, and sleep
- Aggressive physical therapy and activity for neuroplasticity
There's no universal formula. What works depends on your injury level, your specific pain type, your tolerance for side effects, and your life circumstances. The process is genuinely trial-and-error.
The Hard Reality
Complete pain relief after SCI is rare. The realistic goal for most people is meaningful reduction — getting pain from a 9/10 to a 5/10, restoring sleep, enabling function. That's not failure. That's what the evidence actually supports.
What you deserve: a pain specialist (ideally one who knows SCI) who takes your pain seriously, is willing to try multiple approaches, and doesn't dismiss your experience. If your current provider isn't doing that, find a different one.
What the community knows: people with SCI who manage their pain best are usually the ones who built a team — physiatrist, pain specialist, physical therapist, psychologist — rather than relying on one doctor and one drug.
Questions to bring to your doctor
This whole page exists so you can walk into an appointment informed. A few prompts that tend to open up a productive conversation:
- Given my injury level and pain pattern, which first-line option would you start with — and why that one for me?
- What's the plan to titrate up, how long should I give it before we judge whether it's working, and what counts as "working"?
- If a single drug isn't enough, which combination would you consider, and what interactions should we watch (especially serotonin syndrome or extra sedation)?
- Would a topical (lidocaine or capsaicin patch) make sense for my most focused pain area?
- Where do cannabinoids fit for me legally and medically, and how should I start if we try them?
- If we ever consider opioids, what are the goals, the limits, and the plan to come off them?
- Am I a candidate for a pain-specialist referral, interventional options, or neurostimulation?
- Should we check anything (kidney/liver function, vitamin B12, medication levels) before or during treatment?
- Could my pain reflect a new problem (like a syrinx) that needs imaging?
Sources & further reading
These pages summarize clinical guidelines, peer-reviewed research, regulatory records, and manufacturer information in plain language. They are starting points — follow the links for the full detail, and bring anything useful to your care team.
- Bryce TN et al. Treatments perceived helpful for neuropathic pain after SCI (J Spinal Cord Med, 2024) — https://pmc.ncbi.nlm.nih.gov/articles/PMC11044759/
- NINDS — Spinal Cord Injury (mechanisms, treatment) — https://www.ninds.nih.gov/health-information/disorders/spinal-cord-injury
- Northwest Regional SCI System / MSKTC — Pain after SCI — https://sci.washington.edu/info/pamphlets/msktc-pain.asp
- Neuropathic pain: evidence-based recommendations (2024) — https://www.sciencedirect.com/science/article/pii/S0755498224000101
- A comprehensive algorithm for management of neuropathic pain (Pain Medicine) — https://academic.oup.com/painmedicine/article/20/Supplement_1/S2/5509427
- Neuropathic pain in adults — guideline summary (NICE-based) — https://www.iatrox.com/guidelines/neuropathic-pain-in-adults
- Mirogabalin for central neuropathic pain after SCI — Phase 3 (Neurology) — https://www.neurology.org/doi/10.1212/WNL.0000000000201709
- Cannabis-based medicines for chronic neuropathic pain — Cochrane review — https://pmc.ncbi.nlm.nih.gov/articles/PMC6494210/
- Cannabis-based medicines & medical cannabis — dosing/forms review — https://pmc.ncbi.nlm.nih.gov/articles/PMC8732831/
- Opioids for neuropathic pain — Palliative Care Network of Wisconsin — https://www.mypcnow.org/fast-fact/opioids-for-neuropathic-pain/
- The neuropathic pain: current treatment & future approaches — https://pmc.ncbi.nlm.nih.gov/articles/PMC6431761/
- Topical analgesics for neuropathic pain — clinical guide — https://www.medcentral.com/meds/pain/topical-analgesic-use-for-neuropathic-pain-new-clinical-guide
- Capsaicin 8% patch for SCI neuropathic pain (clinical trial) — https://clinicaltrials.gov/study/NCT02441660
- IV ketamine infusions for neuropathic pain (Anesthesia & Analgesia) — https://journals.lww.com/anesthesia-analgesia/abstract/2017/02000/intravenous_ketamine_infusions_for_neuropathic.41.aspx
- Intrathecal ziconotide for refractory SCI neuropathic pain (trial) — https://clinicaltrials.gov/study/NCT03942848
- Botulinum toxin for neuropathic pain — review — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618193/
- Suzetrigine (Journavx / VX-548) — overview — https://www.drugs.com/medical-answers/what-vx-548-3576627/
- Diet & supplements for chronic neuropathic pain — systematic review — https://onlinelibrary.wiley.com/doi/abs/10.1111/papr.13291
- German Society of Neurology — neuropathic pain guideline — https://pmc.ncbi.nlm.nih.gov/articles/PMC7650069/
- Christopher & Dana Reeve Foundation — Paralysis Resource Center — https://www.christopherreeve.org/
- Chronic Pain — MedlinePlus (U.S. National Library of Medicine) — https://medlineplus.gov/chronicpain.html